found elevated expression of CD6 in aggressive NK-cell leukemia/lymphoma (ANKLL) and extranodal NK/T-cell lymphoma (ENKTL), suggesting that CD6 could be a therapeutic target for these hematological malignances (38). The gene discussed is CD6; the disease is cancer.